Dr Reddy's partners with AstraZeneca to promote diabetes drug saxagliptin
As per the deal, Dr Reddy's will distribute Riax (saxagliptin) and Riax M (a fixed dose combination of saxagliptin with metformin) - both brands owned by AstraZeneca - in India
BS B2B Bureau B2B Connect | Hyderabad
Onglyza (saxagliptin), AstraZeneca’s patented therapy, is an oral hypoglycemic (anti-diabetic therapy) in the dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.
Alok Sonig, senior vice president and head of India Business, Dr Reddy’s Laboratories Limited, said, “We are committed to addressing unmet needs of diabetes patients in India and are pleased to partner with AstraZeneca in launching saxagliptin and its combination with metformin, an important addition to our diabetes franchise. This will expand access to innovative medicines to vast number of diabetes patients in India.”
Partnership with AstraZeneca is expected to strengthen Dr Reddy’s diabetes franchise in India. On the other hand, the partnership will enable AstraZeneca to expand usage of this molecule through wider reach to physicians and benefiting more number of diabetic patients.
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: May 30 2015 | 1:43 PM IST